Clinical trial · no report yet · Phase 1/Phase 2
FONTANA
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
- NCT05797168 ↗
- Recruiting
- AstraZeneca
- 15 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 7 | |
| Podcasts | 4 | |
| X threads | 3 | |
| X videos | 1 |
The trial
ClinicalTrials.gov- Official title
- A Modular Phase I/IIa, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Ascending Doses of AZD5335 Monotherapy and in Combination With Anti-cancer Agents in Participants With Solid Tumors
- Phase
- Phase 1/Phase 2
- Status
- Recruiting
- Conditions
- Ovarian Cancer; Lung Adenocarcinoma; Endometrial Cancer; Lung Squamous Cell Carcinoma
- Interventions
- Torvutatug samrotecan; Saruparib; Bevacizumab; Carboplatin; Palacaparib; Pembrolizumab
- Arms
- Module 1: Torvu-sam Monotherapy · Experimental
- Module 2: Torvu-sam + Saruparib · Experimental
- Module 3: Torvu-sam + Bevacizumab · Experimental
- Module 4: Torvu-sam + Carboplatin +/- Bevacizumab · Experimental
- Module 5: Torvu-sam + Palacaparib +/- Bevacizumab · Experimental
- Module 6: Torvu-sam + Pembrolizumab +/- Palacaparib · Experimental
- Enrollment
- 622 (estimated)
- Primary outcomes
- Number of participants with adverse events/serious adverse events
- The number of participants with dose limiting toxicity(DLT), as defined in the protocol
- Sponsor
- AstraZeneca
- Start
- Jun 5, 2023
- Primary completion
- Aug 4, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT05797168 · updated Oct 5, 2026